LUX Infusion Expands Hemophilia Care Access with Qfitlia

LUX Infusion has begun dispensing Qfitlia (fitusiran), a treatment option for individuals aged 12 and older diagnosed with hemophilia A or B. The company states this move will broaden patient access to a unique therapy aimed at routine bleed prevention.

The subcutaneous treatment, Qfitlia, is being integrated into LUX Infusion's care framework designed to remove barriers to treatment access and navigation. This approach aims to provide a more streamlined experience for patients managing their condition.

"Making care easier to not only access, but also navigate is central to our mission," said Ted Kramm, Chief Executive Officer of LUX Infusion. "We hold a deep, long-standing commitment to the bleeding disorder community, and adding Qfitlia to our portfolio enables us to offer a unique treatment option that is fully supported by our high-touch model."

The company offers comprehensive support throughout the treatment process, assisting patients with benefit navigation and appeals, as well as day-to-day treatment management. LUX Infusion's program pairs each patient with a dedicated point of contact experienced in bleeding disorders, backed by 24/7 on-call guidance, and works in conjunction with Hemophilia Treatment Centers.